Professor Sir Chris Evans, Founder and Chief Scientific Officer of EDX Medical, has taken part in a new interview with London South East’s Focus IR, discussing the company’s ambition to become a leading international player in precision cancer diagnostics.
The interview explores EDX Medical’s next phase of development following its move from the Aquis Exchange to AIM, including the company’s commercialisation strategy, growing institutional visibility and plans for international expansion.
Professor Evans also discusses the rollout of EDX Medical’s testicular, bowel and prostate cancer diagnostic platforms, as well as the role of AI, genomics and molecular diagnostics in transforming earlier detection, personalised medicine and preventative healthcare.
